A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations

Trial Profile

A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Entrectinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms STARTRK-1
  • Sponsors Ignyta
  • Most Recent Events

    • 30 Mar 2017 Results from single patient with primary brain tumour harnoring an NTRK1 fusion published in an Ignyta Inc. media release.
    • 30 Mar 2017 Results from single patient with primary brain tumour harnoring an NTRK1 fusion published in Precision Oncology, according to an Ignyta Inc. media release.
    • 09 Feb 2017 According to an Ignyta media release, results from two Phase I trials were published in the journal Cancer Discovery. (Data cutoff September 20, 2016 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top